146 related articles for article (PubMed ID: 25242535)
1. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
2. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
3. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
4. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.
Wang GM; Ren ZX; Wang PS; Su C; Zhang WX; Liu ZG; Zhang L; Zhao XJ; Chen G
Oncol Rep; 2014 Aug; 32(2):573-80. PubMed ID: 24899100
[TBL] [Abstract][Full Text] [Related]
5. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
6. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
Liu Y; Zhang W; Liu S; Liu K; Ji B; Wang Y
Oncol Rep; 2017 Mar; 37(3):1857-1864. PubMed ID: 28184920
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.
Yue Y; Shao Y; Luo Q; Shi L; Wang Z
Biomed Res Int; 2013; 2013():434561. PubMed ID: 23936798
[TBL] [Abstract][Full Text] [Related]
8. Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis.
Chen CL; Wu JC; Chen GY; Yuan PH; Tseng YW; Li KC; Hwang SM; Hu YC
Mol Ther; 2015 Jan; 23(1):79-88. PubMed ID: 25023326
[TBL] [Abstract][Full Text] [Related]
9. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
[TBL] [Abstract][Full Text] [Related]
10. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
Li D; Xiao Z; Wang G; Song X
Mol Med Rep; 2015 Oct; 12(4):5517-23. PubMed ID: 26135838
[TBL] [Abstract][Full Text] [Related]
12. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
Yang CL; Jiang FQ; Xu F; Jiang GX
Tumour Biol; 2012 Oct; 33(5):1535-41. PubMed ID: 22581584
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA-122-5p to regulate ADAM10 expression.
Gao J; Yin X; Yu X; Dai C; Zhou F
J Cell Biochem; 2019 Oct; 120(10):16393-16407. PubMed ID: 31270840
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.
Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866
[TBL] [Abstract][Full Text] [Related]
15. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
Xu Y; Lai Y; Cao L; Li Y; Chen G; Chen L; Weng H; Chen T; Wang L; Ye Y
RNA Biol; 2021 Oct; 18(10):1408-1423. PubMed ID: 33206588
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
17. Taurolidine promotes cell apoptosis by enhancing GRIM‑19 expression in liver cancer.
Li F; Qi J; Qin C; Fu Z; Ren W
Oncol Rep; 2018 Dec; 40(6):3743-3751. PubMed ID: 30272302
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo.
Wen LJ; Gao LF; Jin CS; Zhang HJ; Ji K; Yang JP; Zhao XJ; Wen MJ; Guan GF
Int J Clin Exp Pathol; 2013; 6(10):2071-81. PubMed ID: 24133585
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo.
Zhang W; Shao Y; Du Y; Geng W; Jiang T; Liu H; Zhang D
Mol Med Rep; 2015 Nov; 12(5):7665-72. PubMed ID: 26458553
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
